Is Lonza Group profitable in 2026?

Yes. Lonza's H1 2026 CORE EBITDA margin reached 34.8%, up 4.4 points year on year, and full year 2026 margin guidance was raised to 33-34% as of the July 22, 2026 results release, following a FY2025 margin of 31.6%.

Who is Lonza's biggest competitor?

Samsung Biologics is Lonza's closest rival, with 784,000L of capacity expanding to 1,324,000L by 2032 and a platform licensing push announced June 25, 2026. GEN's leaderboard still ranks Lonza #1 CDMO by sales as of October 2025.

Could AI replace Lonza's manufacturing business?

No. Lonza's core business is physical GMP biologics manufacturing embedded in customer FDA approvals; AI tools like its Design2Optimize route-scouting platform (described October 2025) assist process modeling but cannot substitute for validated bioreactor capacity such as the ~330,000L Vacaville site.

Is Lonza Group growing or slowing down?

Both. FY2025 sales grew 21.7% at constant exchange rates to CHF 6.5 billion (January 28, 2026), but 2026 guidance calls for 11-12% CER growth, a deceleration that triggered a 3.4-4.6% stock drop on the results release.

Who owns Lonza Group?

Lonza is a publicly traded, widely-held Swiss company with no controlling parent, listed as LONN on SIX Swiss Exchange, with a market capitalization of roughly CHF 37.9 billion as of July 24, 2026.

What happened with Lonza's Capsules and Health Ingredients business?

Lonza agreed on March 6, 2026 to sell its CHI unit to Lone Star Funds at a CHF 2.3 billion enterprise value, keeping a 40% stake and taking CHF 1.7 billion upfront cash; the deal is expected to close in H2 2026.

Biotech tools companies · Switzerland

Lonza Group

lonza.com ↗

Swiss contract manufacturer that makes drugs for pharma companies under FDA-approved processes.

Hard to displace

Assessed 24 July 2026 · Evidence as of 24 July 2026

Strong structural protection; the business model survives ai pressure.

On the recordSince 24 July 2026 · Checkable from H2 2026 · Every call on the record Checkpoint: CHI divestment to Lone Star Funds expected to close, completing Lonza's shift to pure-play CDMO

The call

Lonza's business runs on regulatory paperwork and scarce US bioreactor capacity that AI does not touch, while rivals like Samsung Biologics build toward it rather than take from it.

Lonza manufactures biological drugs for pharmaceutical companies that don't make their own. It's difficult to switch suppliers because the FDA requires drug makers to stick with approved manufacturing plants, and building new large-scale facilities takes years and billions of dollars. Samsung Biologics is expanding capacity and WuXi Biologics faces US pressure, but neither has yet displaced Lonza's #1 position. The company's growth is expected to slow from 21.7% in 2025 to 11-12% in 2026, and it is selling a facility called CHI in mid-2026, so the key question is whether profits stay strong as growth normalizes rather than whether the business survives.

Why

AI pressure: None apparent. AI can speed up lab and data work but cannot run GMP bioreactors or replace FDA-locked manufacturing processes. Could AI do the core job? Unlikely.

Bigger players: Samsung Biologics. Samsung is racing to 1.32M L of capacity by 2032 and pushing platform licensing, but has no named contracts pulled from Lonza yet. Could a giant copy it? No, they are blocked.

What protects it. Drug approvals are filed against Lonza's specific manufacturing process and site, so switching means refiling with the FDA, not just picking a cheaper vendor.

What would change this call

Samsung Biologics breaks ground on US mammalian bioreactor capacity rivaling Vacaville's ~330,000L. Would show Lonza's US capacity scarcity moat is being directly challenged.
Lonza's CHI divestment to Lone Star Funds closes on schedule in H2 2026. Confirms clean separation risk is resolved and pure-play CDMO strategy executes as planned.
FY2026 CDMO sales growth lands near guided 11-12% CER versus FY2025's 21.7%. Would confirm expected growth deceleration rather than a deeper demand problem.

Key numbers

FY2025 CDMO sales CHF 6.5B, up 21.7% CER (2026-01-28)
Vacaville site cost $1.2B for 330,000L capacity (2024-10-01)
2026 growth guidance cut to 11-12% CER from 21.7% (2026-07-22)

Named risks

CHI divestment to Lone Star Funds may face regulatory or legal separation delays before H2 2026 close. Severity: medium
Growth deceleration from 21.7% FY2025 CER to guided 11-12% for 2026 pressures investor sentiment. Severity: medium
Cell and Gene site utilization normalization in 2026 remains an open operational question. Severity: low
Active litigation including an employment discrimination suit filed November 2025 against Lonza America. Severity: low
US Section 232 pharma tariff and onshoring policy could shift and remove a current tailwind. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Samsung Biologics	contesting	Expanding to 1.32M L by 2032 and launching platform licensing push, per report dated 2026-06-25
WuXi Biologics	gaining on	US biosecurity pressure since 2024 redirecting contract share toward Lonza and Samsung, per 2025-10-30 report
Catalent (Novo Holdings)	contesting	Acquired by Novo Holdings for $16.5B, closed late 2024, consolidating CDMO capacity
Thermo Fisher Scientific Pharma Services	contesting	Ranked #2 CDMO by sales behind Lonza's #1 spot, per 2025-10-30 leaderboard

Questions people ask

Is Lonza Group profitable in 2026?: Yes. Lonza's H1 2026 CORE EBITDA margin reached 34.8%, up 4.4 points year on year, and full year 2026 margin guidance was raised to 33-34% as of the July 22, 2026 results release, following a FY2025 margin of 31.6%.
Who is Lonza's biggest competitor?: Samsung Biologics is Lonza's closest rival, with 784,000L of capacity expanding to 1,324,000L by 2032 and a platform licensing push announced June 25, 2026. GEN's leaderboard still ranks Lonza #1 CDMO by sales as of October 2025.
Could AI replace Lonza's manufacturing business?: No. Lonza's core business is physical GMP biologics manufacturing embedded in customer FDA approvals; AI tools like its Design2Optimize route-scouting platform (described October 2025) assist process modeling but cannot substitute for validated bioreactor capacity such as the ~330,000L Vacaville site.
Is Lonza Group growing or slowing down?: Both. FY2025 sales grew 21.7% at constant exchange rates to CHF 6.5 billion (January 28, 2026), but 2026 guidance calls for 11-12% CER growth, a deceleration that triggered a 3.4-4.6% stock drop on the results release.
Who owns Lonza Group?: Lonza is a publicly traded, widely-held Swiss company with no controlling parent, listed as LONN on SIX Swiss Exchange, with a market capitalization of roughly CHF 37.9 billion as of July 24, 2026.
What happened with Lonza's Capsules and Health Ingredients business?: Lonza agreed on March 6, 2026 to sell its CHI unit to Lone Star Funds at a CHF 2.3 billion enterprise value, keeping a 40% stake and taking CHF 1.7 billion upfront cash; the deal is expected to close in H2 2026.

Timeline

2026-07-22H1 2026 results: sales CHF 3.4B (+16.0% CER), margin 34.8%, FY margin guidance raised to 33-34%
2026-05-08AGM approves CHF 5.00/share dividend (+25% YoY) and new board members
2026-03-06Lonza agrees to sell CHI business to Lone Star Funds for CHF 2.3B enterprise value
2026-01-28FY2025 results: CHF 6.5B sales (+21.7% CER), 31.6% margin; stock dips 3.4-4.6%
2024-10-01Lonza completes USD 1.2B acquisition of Vacaville biologics site (~330,000L capacity)
2024-07-01Wolfgang Wienand becomes CEO, joining from Siegfried Group
2023-01-01Lonza acquires Synaffix, an antibody-drug conjugate technology company

Revision history

24 July 2026

First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.

In the same band

Merck KGaA (MilliporeSigma)Intertek Group plc Eurofins Scientific SE